Prestige Consumer Healthcare (NYSE:PBH) VP Jeffrey Zerillo Sells 1,000 Shares

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jeffrey Zerillo also recently made the following trade(s):

• On Monday, December 1st, Jeffrey Zerillo sold 281 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $60.00, for a total transaction of $16,860.00.
• On Friday, November 28th, Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $60.00, for a total value of $43,140.00.

Prestige Consumer Healthcare Trading Down 0.2%

Prestige Consumer Healthcare stock opened at $66.81 on Friday. The stock has a 50-day moving average of $63.81 and a two-hundred day moving average of $63.71. The stock has a market cap of $3.16 billion, a PE ratio of 17.67, a price-to-earnings-growth ratio of 2.11 and a beta of 0.43. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. Prestige Consumer Healthcare Inc. has a one year low of $57.25 and a one year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The firm had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after purchasing an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after purchasing an additional 1,289 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after acquiring an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PBH. Canaccord Genuity Group lowered their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus price target of $80.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).